Disruption of Hepatocyte Growth Factor/c-Met Signaling Enhances Pancreatic β-Cell Death and Accelerates the Onset of Diabetes
Open Access
- 21 January 2011
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 60 (2), 525-536
- https://doi.org/10.2337/db09-1305
Abstract
OBJECTIVE: To determine the role of hepatocyte growth factor (HGF)/c-Met on β-cell survival in diabetogenic conditions in vivo and in response to cytokines in vitro. RESEARCH DESIGN AND METHODS: We generated pancreas-specific c-Met-null (PancMet KO) mice and characterized their response to diabetes induced by multiple low-dose streptozotocin (MLDS) administration. We also analyzed the effect of HGF/c-Met signaling in vitro on cytokine-induced β-cell death in mouse and human islets, specifically examining the role of nuclear factor (NF)-κB. RESULTS: Islets exposed in vitro to cytokines or from MLDS-treated mice displayed significantly increased HGF and c-Met levels, suggesting a potential role for HGF/c-Met in β-cell survival against diabetogenic agents. Adult PancMet KO mice displayed normal glucose and β-cell homeostasis, indicating that pancreatic c-Met loss is not detrimental for β-cell growth and function under basal conditions. However, PancMet KO mice were more susceptible to MLDS-induced diabetes. They displayed higher blood glucose levels, marked hypoinsulinemia, and reduced β-cell mass compared with wild-type littermates. PancMet KO mice showed enhanced intraislet infiltration, islet nitric oxide (NO) and chemokine production, and β-cell apoptosis. c-Met-null β-cells were more sensitive to cytokine-induced cell death in vitro, an effect mediated by NF-κB activation and NO production. Conversely, HGF treatment decreased p65/NF-κB activation and fully protected mouse and, more important, human β-cells against cytokines. CONCLUSIONS: These results show that HGF/c-Met is critical for β-cell survival by attenuating NF-κB signaling and suggest that activation of the HGF/c-Met signaling pathway represents a novel strategy for enhancing β-cell protection.Keywords
This publication has 51 references indexed in Scilit:
- Hepatocyte Growth Factor Enhances Engraftment and Function of Nonhuman Primate IsletsDiabetes, 2008
- Hepatocyte Growth Factor Exerts Its Anti-Inflammatory Action by Disrupting Nuclear Factor-κB SignalingThe American Journal of Pathology, 2008
- Glucose Infusion in MiceDiabetes, 2007
- NF-κB prevents β cell death and autoimmune diabetes in NOD miceProceedings of the National Academy of Sciences of the United States of America, 2007
- Nuclear Factor-κB Regulates β-Cell DeathDiabetes, 2006
- Hepatocyte Growth Factor Ameliorates the Progression of Experimental Autoimmune MyocarditisCirculation Research, 2005
- Hepatocyte Growth Factor Suppresses Vascular Endothelial Growth Factor-Induced Expression of Endothelial ICAM-1 and VCAM-1 by Inhibiting the Nuclear Factor-κB PathwayCirculation Research, 2005
- Expression of Transgene Encoded TGF-β in Islets Prevents Autoimmune Diabetes in NOD Mice by a Local MechanismJournal of Autoimmunity, 2002
- Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38Published by Elsevier BV ,2001
- Hepatocyte growth factor/scatter factor‐induced intracellular signallingInternational Journal of Experimental Pathology, 2000